Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Review of Molecular Diagnostics

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737159.8.4.479PMID 18598229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes.

  2009cited by this paper
• Guidelines for the next 10 years of proteomics

  2009cited by this paper
• Diagnostic accuracy of Alzheimer’s disease: A clinicopathological study

  2009cited by this paper
• Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis

  2008cited by this paper
• Long‐chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes

  2008cited by this paper
• Integrated analysis of the cerebrospinal fluid peptidome and proteome.

  2008cited by this paper
• N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry

  2007cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2007cited by this paper
• How common are the “common” neurologic disorders?

  2007cited by this paper
• S100B in neuropathologic states: The CRP of the brain?

  2007cited by this paper
• Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype

  2007cited by this paper
• CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls

  2007cited by this paper
• Use of proteomic approaches to identify disease biomarkers.

  2007cited by this paper
• Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis

  2007cited by this paper
• Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

  2007cited by this paper
• Erythropoietin in Cerebrospinal Fluid: Age-related Reference Values and Relevance in Neurological Disease

  2007cited by this paper
• Endogeneous peptide profiling of cerebrospinal fluid by MALDI‐TOF mass spectrometry: Optimization of magnetic bead‐based peptide capture and analysis of preanalytical variables

  2007cited by this paper
• A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia

  2007cited by this paper
• New movements in neurofilament transport, turnover and disease.

  2007cited by this paper
• Cerebrospinal fluid proteome profile in multiple sclerosis

  2007cited by this paper
• The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis

  2006cited by this paper
• Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis

  2006cited by this paper
• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• The Neurofilament Heavy Chain (NfHSMI35) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease

  2006cited by this paper
• Enzyme-Linked Immunosorbent Assay

  2006cited by this paper
• Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

  2006cited by this paper
• Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway

  2006cited by this paper
• Biomarkers for amyotrophic lateral sclerosis

  2006cited by this paper
• Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

  2006cited by this paper
• Multiple Sclerosis Cerebrospinal Fluid Biomarkers

  2006cited by this paper
• Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

  2006cited by this paper
• Axonal damage markers in cerebrospinal fluid are increased in ALS

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease.

  2006cited by this paper
• Identification of potential CSF biomarkers in ALS

  2006cited by this paper
• REporting recommendations for tumour MARKer prognostic studies (REMARK)

  2005cited by this paper
• Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis

  2005cited by this paper
• Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease

  2005cited by this paper
• Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.

  2005cited by this paper
• Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease.

  2005cited by this paper
• Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis.

  2005cited by this paper
• CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

  2005cited by this paper
• Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis

  2005cited by this paper
• Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study

  2005cited by this paper
• Astroglial expression of ceramide in Alzheimer's disease brains : a role during neuronal apoptosis

  2005cited by this paper
• Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease

  2005cited by this paper
• REporting recommendations for tumour MARKer prognostic studies (REMARK)

  2005cited by this paper
• Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins.

  2005cited by this paper
• CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment

  2005cited by this paper
• CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

  2005cited by this paper
• Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis

  2005cited by this paper
• Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG

  2004cited by this paper
• Neurofilament and glial fibrillary acidic protein in multiple sclerosis

  2004cited by this paper
• CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS

  2004cited by this paper
• Amyotrophic lateral sclerosis with dementia: The clinicopathological spectrum

  2004cited by this paper
• Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients

  2004cited by this paper
• Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis

  2004cited by this paper
• Cerebrospinal fluid levels of brain specific proteins in optic neuritis

  2004cited by this paper
• Development of biomarkers in multiple sclerosis.

  2004cited by this paper
• Unraveling the mechanisms involved in motor neuron degeneration in ALS.

  2004cited by this paper
• The 14-3-3 protein in multiple sclerosis: a marker of disease severity

  2004cited by this paper
• Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

  2004cited by this paper
• Evidence for pathogenic heterogeneity in multiple sclerosis

  2004cited by this paper
• Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.

  2004cited by this paper
• Proteomic analysis of multiple sclerosis cerebrospinal fluid

  2004cited by this paper
• Elevated neurofilament levels in neurological diseases.

  2003cited by this paper
• Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease.

  2003cited by this paper
• Cerebrospinal fluid S-100 protein levels in neurological pathologies

  2003cited by this paper
• [Level of S-100 and neuron-specific enolase in cerebrospinal fluid from subjects with neurological pathologies].

  2003cited by this paper
• Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

  2003cited by this paper
• Intracranial arterial dolichoectasia and its relation with atherosclerosis and stroke subtype

  2003cited by this paper
• Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias

  2003cited by this paper
• The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration

  2003cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

  2003cited by this paper
• A specific ELISA for measuring neurofilament heavy chain phosphoforms.

  2003cited by this paper
• Amyotrophic lateral sclerosis: A review of current concepts

  2003cited by this paper
• A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

  2003cited by this paper
• Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease.

  2003cited by this paper
• Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

  2003cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Niveles de S-100 y enolasa neuroespecífica en líquido cefalorraquídeo de enfermos con patología neurológica

  2003cited by this paper
• Approaching complete peroxisome characterization by gas‐phase fractionation

  2002cited by this paper
• Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.

  2002cited by this paper
• Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

  2002cited by this paper
• Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis

  2002cited by this paper
• Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

  2002cited by this paper
• Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins.

  2002cited by this paper
• Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients

  2002cited by this paper
• CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

  2002cited by this paper
• Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

  2002cited by this paper
• Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients.

  2002cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2002cited by this paper
• Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.

  2002cited by this paper
• Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

  2002cited by this paper
• 14-3-3 Protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease.

  2002cited by this paper
• Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease.

  2002cited by this paper
• 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis

  2002cited by this paper
• Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt–Jakob disease

  2001cited by this paper
• Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.

  2001cited by this paper
• The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia

  2001cited by this paper

• Analyzing N-Glycans in Cerebrospinal Fluid: A Glycomics Approach.

  2025cites this paper
• Transformative biomedical devices to overcome biomatrix effects.

  2025cites this paper
• Machine Learning-Enhanced Cerebrospinal Fluid N-Glycome for the Diagnosis and Prognosis of Primary Central Nervous System Lymphoma.

  2025cites this paper
• Brain white matter damage biomarkers.

  2025cites this paper
• Cerebrospinal fluid transcripts may predict shunt surgery responses in normal pressure hydrocephalus.

  2023cites this paper
• Comprehensive Assessment of Human Cerebrospinal Fluid for Protein Bio-Marker Identification Following Japanese Encephalitis Viral Infection

  2023cites this paper
• Development of a strategy for assessing blood-brain barrier disruption using serum S100 calcium-binding protein B and neuron-specific enolase in early stage of neuroemergencies: A preliminary study

  2022cites this paper
• Blood GFAP as an emerging biomarker in brain and spinal cord disorders

  2022cites this paper
• Transcriptomic profiling of cerebrospinal fluid predicts shunt surgery responses in patients with Normal Pressure Hydrocephalus

  2022cites this paper
• Cerebrospinal Fluid Proteomics in Friedreich Ataxia Reveals Markers of Neurodegeneration and Neuroinflammation

  2022cites this paper
• Extracellular mitochondria in the cerebrospinal fluid (CSF): potential types and key roles in central nervous system (CNS) physiology and pathogenesis.

  2021cites this paper
• N-Glycomics of Cerebrospinal Fluid: Method Comparison

  2021cites this paper
• Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease

  2021cites this paper
• Candidate metabolic biomarkers for schizophrenia in CNS and periphery: Do any possible associations exist?

  2020cites this paper
• Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

  2019cites this paper
• Theme 6 Tissue biomarkers

  2019cites this paper
• Disease Detection with Molecular Biomarkers: From Chemistry of Body Fluids to Nature-Inspired Chemical Sensors.

  2019cites this paper
• N-glycan profile of cerebrospinal fluids from Alzheimer's Disease patients using LC-MS.

  2019cites this paper
• SWATH Mass Spectrometry Applied to Cerebrospinal Fluid Differential Proteomics: Establishment of a Sample-Specific Method.

  2019cites this paper
• Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS

  2018cites this paper
• Trait and state biomarkers for psychiatric disorders: Importance of infrastructure to bridge the gap between basic and clinical research and industry

  2018cites this paper
• Theme 6 Tissue biomarkers

  2018cites this paper
• Comprehensive Glycomics for the Discovery of New Biomarkers in Neurodegenerative Diseases [an abstract of dissertation and a summary of dissertation review]. 論文内容の要旨

  2018cites this paper
• Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies

  2017cites this paper
• Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis.

  2017cites this paper
• Electrical conductivity and permittivity maps of brain tissues derived from water content based on T1‐weighted acquisition

  2017cites this paper
• Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

  2016cites this paper
• Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease

  2016cites this paper
• Further development of biomarkers in amyotrophic lateral sclerosis

  2016cites this paper
• Specific Metabolome Profile of Exhaled Breath Condensate in Patients with Shock and Respiratory Failure: A Pilot Study

  2016cites this paper
• Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies*

  2016cites this paper
• PAMP-DAMPs interactions mediates development and progression of multiple sclerosis.

  2016cites this paper
• Metabolomics in amyotrophic lateral sclerosis: how far can it take us?

  2016cites this paper
• Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis

  2016cites this paper
• Cerebrospinal Fluid Mechanics and Its Coupling to Cerebrovascular Dynamics

  2016cites this paper
• Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery.

  2016cites this paper
• Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

  2015cites this paper
• Ethanol contamination of cerebrospinal fluid during standardized sampling and its effect on 1H-NMR metabolomics

  2015cites this paper
• A survey of state-of-the-art surface chemistries to minimize fouling from human and animal biofluids.

  2015cites this paper
• Decreased levels of guanosine 3′, 5′‐monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

  2015cites this paper
• T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study

  2015cites this paper
• Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study

  2015cites this paper
• Neuroantibody Biomarkers: Links and Challenges in Environmental Neurodegeneration and Autoimmunity

  2014cites this paper
• Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis

  2014cites this paper
• Untargeted 1H-NMR metabolomics in CSF

  2014cites this paper
• The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog

  2014cites this paper
• Decreased levels of cGMP in CSF are associated with cognitive decline and amyloid pathology in Alzheimer ’ s disease 1 Authors :

  2014cites this paper
• Cytokine Concentrations in the Cerebrospinal Fluid of Great Danes with Cervical Spondylomyelopathy

  2014cites this paper
• Biological and neuroimaging biomarkers for amyotrophic lateral sclerosis: 2013 and beyond

  2013cites this paper
• Differentiation of Progressive Supranuclear Palsy: clinical, imaging and laboratory tools

  2013cites this paper
• Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery

  2013cites this paper
• Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach

  2013cites this paper
• Molecular biomarkers of neurodegeneration

  2013cites this paper
• Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry.

  2013cites this paper
• Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression.

  2012cites this paper
• CSF markers in amyotrophic lateral sclerosis

  2012cites this paper
• Biomarkers in the Clinical Diagnosis and Management of Traumatic Brain Injury

  2012cites this paper
• Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament.

  2012cites this paper
• Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients

  2012cites this paper
• Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

  2012cites this paper
• Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis

  2011cites this paper
• Cerebrospinal fluid markers of idiopathic intracranial hypertension: Is the renin-angiotensinogen system involved?

  2011cites this paper
• Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.

  2011cites this paper
• Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy.

  2011cites this paper
• S100B protein in neurodegenerative disorders

  2011cites this paper
• Correlation of cerebral spinal fluid pH and HCO3- with disease progression in ALS.

  2011cites this paper
• Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis of cerebrospinal fluid using nuclear magnetic resonance spectroscopy.

  2011cites this paper
• Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis

  2011cites this paper
• Clinical biomarkers in multiple sclerosis.

  2011cites this paper
• Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS).

  2010cites this paper
• Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers

  2010cites this paper
• 2D DIGE of the cerebrospinal fluid proteome in neurological diseases

  2010cites this paper
• Glycoproteomics in neurodegenerative diseases.

  2010cites this paper
• CSF phospho-tau is independent of age, cognitive status and gender of neurological patients

  2010cites this paper
• Establishment and Applications of a Multiple Sclerosis Biobank Analysis of Biomarkers and Therapeutic Complications in MS

  2010cites this paper
• Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases

  2010cites this paper
• 1H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis

  2010cites this paper
• CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.

  2009cites this paper
• Cerebrospinal fluid biomarkers in multiple sclerosis.

  2009cites this paper
• Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis.

  2009cites this paper
• Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?

  2009cites this paper
• Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid.

  2009cites this paper
• Unsolved Medical Problems: Blood-brain barrier in neurodegenerative diseases: perspectives for Nanomedicine

  2009cites this paper